Drugs / ZR202-CoV
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05490108 | Jun → Sep 2022 | COVID-19 | Shanghai Zerun Biotechnology Co.,Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT05313022 | Jan → May 2022 | COVID-19 | Shanghai Zerun Biotechnology Co.,Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZR202-CoV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05490108 ↗ |
| Modality | Vaccine | “Adjuvanted Recombinant SARS-CoV-2 S-protein Subunit Vaccine” NCT05313022 ↗ |
| Route | Intramuscular | “administered as 2 injections (i.m) at 28 days apart” NCT05313022 ↗ |